Try our Advanced Search for more refined results
Health
-
January 13, 2026
Express Scripts Can't Impel FTC Atty Views On Insulin Makers
A Federal Trade Commission in-house judge has denied a bid from Express Scripts to force a commission attorney to sit for a deposition to discuss an investigation into insulin manufacturers as the pharmacy benefit manager defends against the agency's insulin pricing case.
-
January 13, 2026
Ga. Panel Doesn't Blink At $50M Bungled Root Canal Verdict
The Georgia Court of Appeals appeared skeptical Tuesday of an Atlanta dentist's bid to overturn a $50 million malpractice verdict against him over a botched root canal, doubting that the award necessarily "shocks the conscience" merely because an earlier, smaller verdict was thrown out on that basis.
-
January 12, 2026
CareFirst Opposes J&J's Bid To Revisit Stelara Antitrust Case
Insurer CareFirst urged a Virginia federal court to reject Johnson & Johnson's bid for reconsideration of a ruling that refused to toss antitrust and patent fraud claims over the immunosuppressive drug Stelara.
-
January 12, 2026
The Curious, Very Long Delay In A Pioneering Drug Prices Suit
When Merck & Co. launched a fiery challenge to Medicare's landmark drug price negotiations, it blazed a trail for many similar suits. But 31 months later, the challenge is stalled where it started as Merck begs for a ruling, other suits speed along the path it created and huge costs now seem unavoidable.
-
January 12, 2026
7th Circ. Finds DEA, State Officials Immune In Pill Mill 'Mess'
The Seventh Circuit Monday overturned rulings that would have let a doctor's Fourth and Fifth amendments claims over a pill mill investigation go to trial, concluding federal and state officials are entitled to immunity in proceedings the court described as a "tangled mess."
-
January 12, 2026
Texas Court Says Medical Expert Wrongly Excluded At Trial
A Texas appellate court has reversed a defense verdict and ordered a new trial in a suit accusing three doctors of negligent post-operative treatment for a gallbladder patient that caused sepsis and ultimately death, saying the trial court wrongly excluded the testimony of the plaintiff's sole expert witness.
-
January 12, 2026
7th Circ. Won't Rehear Psychiatrists' Antitrust Suit Revival Bid
The Seventh Circuit is standing firm on a panel majority's refusal to revive an antitrust suit challenging the American Board of Psychiatry and Neurology's certification maintenance requirement, having refused to rehear appellate arguments over a lower court decision tossing the case.
-
January 12, 2026
Elevance Nurses Are Owed No OT, Judge Told As Trial Opens
Elevance Health Inc. said Monday that claims it violated labor law by denying overtime pay to registered nurses evaluating insurance claims are "preposterous," as a Georgia federal bench trial kicked off over a suit from nearly 40 nurses alleging they were stiffed on years of pay.
-
January 12, 2026
Feds To Drop Appeal In 340B Rebate Pilot Challenge
The U.S. Department of Health and Human Services on Monday suggested it will end its appeal of a First Circuit order temporarily blocking it from instituting a rebate program that would change how the agency distributes payments in the federal 340B drug discount program that provides medications at reduced costs to low-income Americans.
-
January 12, 2026
ERISA Recovery Suit Against UnitedHealth Proceeds With Trims
A UnitedHealth plan participant who was injured in a car crash may pursue claims under the Employee Retirement Income Security Act's civil enforcement provision, an Ohio federal court ruled Friday, while also allowing his wife, who was involved in a separate accident, to proceed with certain state-law claims.
-
January 12, 2026
Yale Asks Judge To Rethink $32M Baby Formula Death Verdict
Yale University and the affiliated Yale New Haven Hospital have asked a Connecticut state court judge to reconsider a verdict of nearly $32 million over the death of a premature baby, contending that she failed to grasp battery and informed consent law when issuing her decision after a bench trial.
-
January 12, 2026
15,000 Nurses Begin Strike On Major NYC Hospitals
Thousands of nurses at three New York City hospital systems walked off the job Monday, heralding what their union called the largest nurses' strike in the city's history after the systems refused to meet workers' demands on staffing, benefits and work safety protocol during contract negotiations.
-
January 12, 2026
DC Circ. Told $100K H-1B Fee Threatens Congress' Tax Power
The U.S. Chamber of Commerce urged the D.C. Circuit to bar the Trump administration from charging employers its new $100,000 H-1B visa fee, arguing it presents a "grave threat" to Congress' exclusive power to levy taxes.
-
January 12, 2026
HHS' Pediatric Health Cuts Blocked As Likely 'Retaliatory'
A D.C. federal judge has temporarily blocked the U.S. Department of Health and Human Services from cutting nearly $12 million in pediatric health funding to the American Academy of Pediatrics, finding HHS could be retaliating for a lawsuit challenging the agency's changes to members on a federal vaccine committee.
-
January 12, 2026
Medicine Biz Mirador Wraps $250M Funding Round
San Diego-based clinical-stage precision medicine company Mirador Therapeutics Inc. announced Monday that it closed its Series B funding round with $250 million of investor commitments, bringing the company's total capital raised since its March 2024 launch to more than $650 million.
-
January 12, 2026
Justices Nix Petition On Legal Malpractice Arbitration
The U.S. Supreme Court declined Monday to review a petition that sought clarity on whether a court or arbitrator decides the issue of class arbitrability when the parties incorporate certain arbitral rules, in a long, winding legal malpractice dispute involving Louisiana medical companies.
-
January 12, 2026
Justices Want SG Input On Arthritis Drug Competition Fight
The U.S. Supreme Court on Monday asked the Trump administration to weigh in on whether state unfair competition claims should be used to block a competitor from selling compounded versions of drugs in certain states.
-
January 12, 2026
High Court Won't Take On No Surprises Act Enforcement Row
The U.S. Supreme Court on Monday declined to weigh in on whether the No Surprises Act denies providers a private right to enforce dispute resolution awards against insurers over emergency care coverage.
-
January 12, 2026
No High Court Review For California Opioid 'Nuisance' Suit
The U.S. Supreme Court on Monday said it would not weigh in on a circuit court decision that a California public nuisance lawsuit against pharmacy benefit managers over their opioid-dispensing practices belongs in state court.
-
January 12, 2026
Justices Pass On Houston Hospital Workers' COVID Vax Fight
The U.S. Supreme Court declined Monday to hear a challenge to a Houston hospital's win in a lawsuit brought by a group of employees who said they were unlawfully terminated after refusing the COVID-19 vaccine.
-
January 12, 2026
Justices Won't Weigh Collective Cert. Process In Eli Lilly Case
The U.S. Supreme Court declined on Monday to review whether courts should stick with a long-standing two-step analysis for certifying collective actions in an age discrimination case against Eli Lilly and Co. that could have affected wage and hour litigation.
-
January 09, 2026
Mangione Says Defective Charges Doom Federal Murder Rap
Counsel for Luigi Mangione on Friday urged a Manhattan federal judge to throw out the most serious charges brought against the alleged killer of UnitedHealthcare CEO Brian Thompson, saying prosecutors have failed to allege crimes of violence as predicate offenses to support murder and weapons charges.
-
January 09, 2026
Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims
A Connecticut federal judge on Friday refused to hand a quick win to Mylan Pharmaceuticals and Aurobindo Pharma USA in sprawling antitrust litigation against 26 total pharmaceutical companies, ruling that a coalition of states has enough evidence to raise a genuine dispute about whether the companies conspired to fix drug prices.
-
January 09, 2026
Up Next At High Court: Pollution Lawsuits & Trans Athletes
The U.S. Supreme Court will kick off the new year by hearing disputes over the constitutionality of state laws banning transgender female athletes from female-only sports and whether state or federal courts are the proper forum for lawsuits seeking to hold major oil companies accountable for harm caused by their oil production activities along Louisiana's coast.
-
January 09, 2026
$500K Revelation Doesn't Nix Surgeon's Win In Eye Injury Row
A California appeals court won't order a retrial in a suit alleging a surgery center blinded a patient in one eye during spinal surgery, saying she failed to properly object to a closing argument that implied that a co-defendant's settlement was the source of $500,000 she had received.
Expert Analysis
-
Steps For Healthcare Providers After Cigna ERISA Settlement
Following the Cigna class action's settlement, where Employee Retirement Income Security Act violations arose from Cigna's online provider directory advertising providers as in-network who were actually out-of-network, providers should routinely audit their contract status and directory listings, and proactively coordinate with plans and payor partners, say attorneys at ArentFox Schiff.
-
DOJ's UnitedHealth Settlement Highlights New Remedies Tack
The use of divestitures and Hart-Scott-Rodino Act compliance in the recent U.S. Department of Justice settlement with UnitedHealth Group and Amedisys underscores the DOJ Antitrust Division's willingness to utilize merger remedies under the second Trump administration, say attorneys at Buchanan Ingersoll.
-
When Atty Ethics Violations Give Rise To Causes Of Action
Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.
-
What's New In FDA's Latest Cell And Gene Therapy Guidance
New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.
-
H-1B Fee Guidance Is Helpful But Notable Uncertainty Persists
Recent guidance narrowing the scope of the $100,000 entry fee for H-1B visas will allow employers to plan for the hiring season, but a lack of detail about the mechanics of cross-agency payment verification, fee exemptions and other practical matters still need to be addressed, say attorneys at Klasko Immigration Law Partners.
-
Risk Mitigation For Psychedelic Use In Reproductive Health
With the rising use of psychedelics among women of reproductive age and the absence of clear professional guidelines regarding risk labeling, healthcare providers and facilitators should adopt proactive, evidence-based approaches to mitigate malpractice liability risks, say Kimberly Chew at Husch Blackwell and Sara Shoar at the University of Southern California.
-
Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split
In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.
-
Series
Practicing Stoicism Makes Me A Better Lawyer
Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.
-
Adapting To Enforcement Focus On Wound Care Fraud
As federal agencies target wound care industry fraud as a top enforcement priority, attorneys advising industry stakeholders should evaluate business relationships for Anti-Kickback Statute violations, emphasize appropriate product use and documentation, and use internal data analytics to monitor billing patterns, say David Tarras at Tarras Defense and Jay McCormack at Verrill Dana.
-
Series
The Biz Court Digest: Texas, One Year In
A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.
-
AI Product Safety Insights May Expand Foreseeability
Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.
-
AG Watch: Illinois A Key Player In State-Level Enforcement
Illinois Attorney General Kwame Raoul has systematically strengthened his office to fill federal enforcement gaps, oppose Trump administration mandates and advance state policy objectives, particularly by aggressively pursuing labor-related issues, say attorneys at Troutman.
-
Series
Law School's Missed Lessons: Educating Your Community
Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.
-
Organ Transplant System Reforms Mark Regulatory Overhaul
Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.
-
Federal Grantees May Soon Face More Limitations On Speech
If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.